Clinical Trial Update: Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial evaluates radioimmunotherapy conditioning with 131I-apamistamab before allogeneic stem cell transplantation in patients with relapsed or ref…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• 131I-Apamistamab (131I-apamistamab)

Snippet

Sponsor: Actinium Pharmaceuticals | Conditions: Acute Leukemia, Myeloid Leukemia | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING